Concerto Biosciences raises $23 million Series A
Concerto Biosciences raised $23 million to advance its microbial discovery platform, product pipeline and first-in-human development work.
Evidence notes
- Safar Partners led the Series A with Horizons Ventures and M Ventures among the participants.
- The round supports kChip and kAI development and expansion of the company’s microbial product pipeline.
- Concerto planned partnerships across healthcare, agriculture and consumer applications.